MBL
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

MBL Trademark

Serial Number: 97622009

MBL is a trademark filed by MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. on October 6, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (5 trademarks)

2-11-8 Shibadaimon
Minato-ku, Tokyo 105-0012 , JP

Entity Type: 99

Trademark Details

Filing Date

October 6, 2022

Registration Date

Not Registered

Published for Opposition

May 6, 2025

Goods & Services

Chemical reagents for medical purposes in the fields of cancer, cardiology, autoimmunity and immunological disorders, respiratory diseases, apoptosis, signal transduction, DNA, proteomics and genomics; Reagents for use in medical genetic testing; Immunoassay reagents for medical use; Diagnostic biomarker reagents for medical purposes; Companion diagnostics, namely, medical diagnostic reagents that assist in predicting the effects of a drug, the presence or absence of side effects, and the choice of patients to administer

Testing, analysis and evaluation for approval of goods and services of others to ensure compliance with industry standards; Research and development services in the field of pharmaceutical products; Research and development services in the field of antibodies; Laboratory research services in the field of pharmaceuticals using experimental animals; Cell culture services for scientific and research purposes, for others; Stem cell research services; Consulting services in the field of biotechnology; Laboratory research services relating to pharmaceuticals, in vitro diagnostics, treatment or diagnostics; Medical and scientific research in the field of cancer treatment and diagnosis; Medical laboratory services; Medical research services in the field of cancer; Pharmaceutical drug development support services, namely, pharmaceutical research and development; Scientific and technological services, namely, analyzing preclinical oncology efficacy in the field of medical treatment

Filing History

TEAS STATEMENT OF USE RECEIVED
Dec 29, 2025 EISU
TEAS REQUEST TO DIVIDE RECEIVED
Dec 29, 2025 ERTD
SOU TEAS EXTENSION RECEIVED
Dec 29, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 1, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 6, 2025 NPUB
PUBLISHED FOR OPPOSITION
May 6, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 30, 2025 NONP
EXPARTE APPEAL TERMINATED
Apr 7, 2025 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 7, 2025 CNSA
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sep 24, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Sep 24, 2024 GNSL
SUSPENSION LETTER WRITTEN
Sep 24, 2024 CNSL
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 12, 2024 ERFR
EX PARTE APPEAL-INSTITUTED
Jul 12, 2024 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Jul 12, 2024 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Jul 12, 2024 EXAF
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Apr 12, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Apr 12, 2024 XELR
ASSIGNED TO EXAMINER
Feb 20, 2024 DOCK
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 12, 2024 GNFN
FINAL REFUSAL E-MAILED
Jan 12, 2024 GNFR
FINAL REFUSAL WRITTEN
Jan 12, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 6, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 6, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 6, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 4, 2023 GNRN
NON-FINAL ACTION E-MAILED
Aug 4, 2023 GNRT
NON-FINAL ACTION WRITTEN
Aug 4, 2023 CNRT
ASSIGNED TO EXAMINER
Jul 20, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 23, 2022 NWOS
NEW APPLICATION ENTERED
Oct 10, 2022 NWAP